Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 431 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... September 21, 2020 ESMO’s Special Consultative Status with United Nations Economic and Social Council... October 10, 2025 An integral part of research September 21, 2022 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 Load more HOT NEWS FDA Approves New Dosing Regimen for Cetuximab FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21...
